503 - A phase I,II trial of autologous dendritic cell tumor vaccine combined with irradiation patients with refractory metastatic colorectal cancer

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Clinical research
Colon and Rectal Cancer
Basic Scientific Principles
Presenter Young Jin Choi
Authors Y.J. Choi1, Y.M. Seol2, H.J. Kim2, J.S. Chung2, G.J. Cho2
  • 1Hemato- Oncolgy, Pusan National University Hospital, 602-739 - Busan/KR
  • 2Hemato- Oncology, Pusan National University Hospital, 602-739 - Busan/KR



A dendritic cell vaccine has been developed as a novel strategy for generating antitumor immunity in the treatment of cancer. The purpose of this study was to assess the maximal tolerated dose, safety, clinical efficacy and immunologic response of a new dendritic cell vaccine (DC-Vac) combined with irradiation in patients with metastatic colorectal cancer.

Methods (Materials)

22 patients with metastatic colorectal cancer were assigned to study that received 3, 6, or 12 × 106 DC-Vac 3 times at 2 week intervals and additional 2 times at 4 weeks intervals. On the day before and on the day of each vaccination, each patient received a 4 Gy radiation dose to the target tumor. On the day of vaccination, the indicated dose of autologus DCs was injected in to the irradiated tumor using ultrasound-guided needle injection procrdure. We also evaluated immunologic and tumor responses.


The maximum dose of DC-Vac (12 × 106) was shown to be safe. In 5 of 9 patients, the vaccine resulted in increased interferon (IFN)-_ production by CD8+ cells after exposure to tumor lysate. The response evaluation was performed in 15 of the 17 patients who received at least 4 injections. Stable and progressive disease was found in 4 and 11 patients, respectively.


The DC-based immunotherapy and radiotherapy is theoretically synergistic for the local control and systemic control. The DCVac/IRⓡ immunotherapy combined with irradiation was tolerable and safe in the evaluated cases of refractory metastatic colorectal cancer. Future work should include well designed a phase II clinical trials.


All authors have declared no conflicts of interest.